2008 Heparin sodium incident: "Heparin sodium" produced by the American company Baxter caused adverse drug events in the United States. The United States claimed that some of its raw materials came from Changzhou Kaipu Biochemical Co., Ltd. in China.

The “Erqi Er Yao” Incident: Starting from April 19, 2006, 11 patients were injected with the “Er Qi Er Yao” Leupactin, which was later identified as a counterfeit drug, while receiving treatment at Zhongshan Third Hospital. After injection, poisoning reactions such as kidney failure occurred, and 9 people died one after another.

Xinfu incident: On July 24, 2006, some patients in Xining, Qinghai, developed clinical symptoms such as chest tightness, palpitations, and palpitation after using "Xinfu". The Qinghai Food and Drug Administration immediately issued an emergency notice. Ask the province to deactivate it. Subsequently, the Food and Drug Administration of Guangxi, Zhejiang, Heilongjiang, Shandong and other provinces also reported that patients developed similar clinical symptoms after using the injection.

Jiangxi Boya Globulin Incident: Between May 22 and 28, 2008, the Second Affiliated Hospital of Nanchang University caused 6 accidental deaths due to the use of Jiangxi’s “Boya Immunoglobulin” vaccine.

Methotrexate incident: In July 2007, the National Adverse Drug Reaction Monitoring Center received reports one after another that leukemia patients in some hospitals in Guangxi and Shanghai experienced adverse reaction symptoms such as lower limb pain, fatigue, and difficulty walking. They all used injectable "methotrexate" produced by Shanghai Hualian Pharmaceutical Factory. It was later discovered that pharmaceutical personnel mixed vincristine sulfate tail liquid with "methotrexate", causing multiple batches of drugs to be contaminated and causing a major drug production quality liability accident.

Acanthopanax incident: On October 5, 2008, six patients at the Fourth People's Hospital of Honghe Prefecture suffered serious adverse reactions after using Acanthopanax injection labeled as produced by Wandashan Pharmaceutical Factory in Heilongjiang Province. As of October 7, three patients had died.

Shuanghuanglian incident: In November 2001, the National Adverse Drug Reaction Monitoring Center reported adverse reactions caused by Shuanghuanglian injection for the first time. After the notification was issued, adverse reactions and even deaths occurred frequently in patients caused by the injection of Shuanghuanglian Injection.

Xiangdan incident: In March 2009, 13 patients at Zhongshan Sanxiang Hospital who had suspected adverse reactions due to the use of Xiangdan injection resolved their symptoms within 2 hours that day. On March 24, the Ministry of Health issued an emergency notice requiring medical institutions at all levels to immediately stop using Xiangdan Injection with batch number 080524 produced by Zhejiang Tianrui Pharmaceutical Co., Ltd.